Opinion|Videos|July 18, 2024
Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis
Author(s)Shawn Kwatra, MD
Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What characteristics, if any, of oral JAK inhibitors make them an attractive option for improving QoL in patients with AD?
- Discuss clinical trial data with oral JAK inhibitors, upadacitinib and abrocitinib, and improvements in patient-reported outcomes in atopic dermatitis.
- Please review data from real-world studies that have evaluated effectiveness of oral JAK inhibitors (upadacitinib and abrocitinib) through physician and patient-reported outcomes.
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
4
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
5